A recent preclinical study identified Bcl-2 as a key therapeutic target and demonstrated the efficacy of a selective Bcl-2 inhibitor, venetoclax, in hypodiploid ALL, providing a promising treatment strategy to improve outcome in this disease [42]. Here, BCL2 is linked to acute lymphoblastic leukemia.